A Phase 1 Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies

Trial Profile

A Phase 1 Trial of PXD101 in Combination With 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Belinostat (Primary) ; Isotretinoin
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 10 Jun 2016 Planned primary completion date changed from 1 May 2016 to 1 Dec 2016.
    • 08 Dec 2015 Planned primary completion date changed from 1 Oct 2015 to 1 May 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top